What is Gilead Sciences?
Headquartered in Foster City, California, Gilead Sciences operates as a research-based biopharmaceutical entity dedicated to the discovery, development, and commercialization of transformative medicines. The company maintains a robust portfolio spanning HIV/AIDS treatments, viral hepatitis therapies, and oncology solutions. By leveraging a sophisticated network of collaboration agreements with entities such as Arcus Biosciences and Merck & Co, Gilead effectively bridges the gap between early-stage scientific discovery and commercial-scale distribution. Its market authority is anchored by flagship products like Biktarvy and Veklury, which serve as cornerstones for its sustained revenue growth and clinical influence in the United States, Europe, and beyond.
How much funding has Gilead Sciences raised?
Gilead Sciences has raised a total of $296.3M across 2 funding rounds:
Stock Offering
$86.3M
Other Financing Round
$210M
Stock Issuance/Offering (1992): $86.3M, investors not publicly disclosed
Other Financing Round (2024): $210M led by Abingworth
Key Investors in Gilead Sciences
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that transforms cutting-edge science into novel medicines by providing capital and expertise to top-tier management teams.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Gilead Sciences?
Looking ahead, Gilead Sciences is poised to leverage its recent capital infusion to accelerate its research and development initiatives, particularly in the oncology and immunology sectors. The strategic allocation of these funds will likely focus on deepening its research collaboration and license agreements, such as those with Merus N.V. for trispecific antibody development. As the company navigates the complexities of global health challenges, its focus remains on expanding its therapeutic reach and optimizing its clinical co-development strategies. This financial trajectory suggests a continued emphasis on high-impact medical innovation, ensuring that Gilead remains at the forefront of the biopharmaceutical industry's evolution toward precision medicine and targeted therapeutic interventions.
See full Gilead Sciences company page
